Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

We are delighted to announce the launch of our Imperial College Enterprise Fund (ICEF) III. The Fund is managed by Parkwalk in conjunction with Imperial Enterprise. The Fund invests in early-stage hard science and disruptive technology companies, linked to Imperial College, one of the world’s top 10 ranked universities.

Tuesday 16 January 2024, London: Parkwalk today announced the launch of the Imperial College Enterprise Fund (ICEF) III, the third in a series with Imperial College Enterprise. The new Fund will once again invest in companies seeking to commercialise discoveries linked to Imperial College, enabling investors to support the introduction of innovative technologies whilst generating attractive returns and benefitting from incentives provided under the Enterprise Investment Scheme.

Previous Imperial College Enterprise Funds have provided backing to 10+ early-stage science and tech-based businesses, such as: Charco Neurotech – a developer in a non-invasive wearable device for reducing Parkinson’s symptoms, FreshCheck – a novel colour change technology to detect bacterial contamination on surfaces and GripAble – a med-tech company that has created gamified rehabilitation through sensor-based medical devices and software, replicating hospital therapy at home.

The third Fund will continue to invest in early-stage, high-growth, research-intensive companies. These spin-outs are based directly on academic research, deep science businesses developed by students, or companies emerging from Imperial’s innovation ecosystem. The Fund will support companies founded on Imperial’s research, helping transform these new scientific discoveries into tomorrow’s solutions.

Imperial College London has a long history of producing ground-breaking scientific research and disruptive technologies and is globally ranked in the world’s top 10 universities. It has a thriving entrepreneurial ecosystem and has seen close to 200 start-ups formed in the last five years alone, attracting close to £0.5bn in external capital, and supporting the creation of over 1,300 new jobs. In the most recent Research Excellence Framework, a formal assessment of all UK university research, ranked Imperial first for research outputs and first for research environment impact (among Russell Group universities).

Martin Glen, Investment Director at Parkwalk, said: “We are pleased to launch the third fund with the team at Imperial College Enterprise, which has an innovative ecosystem of deep science and technology businesses. With our expertise in scaling and commercialising early-stage university spin-outs, and Imperial College’s impressive global top-10 position in R&D, we are excited to be supporting the next wave of entrepreneurs.”

Parkwalk is the largest growth EIS Fund Manager and backs world-changing technologies emerging from the UK’s leading universities and research institutions. With £500m of assets under management, the company has invested in over 160 companies across its own funds and those it manages for Imperial College London and others.

Find out more information about the Fund here. To request fund documentation or more information on the Imperial College Enterprise Fund III please email our team at [email protected].

Parkwalk Advisors Limited (Parkwalk) is authorised and regulated by the Financial Conduct Authority: FRN 502237. Investments referred to in this news article are not suitable for all investors. Capital is at risk and investors may not get back the full amount invested. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Tax treatment depends on the individual circumstances of each investor. Parkwalk is not able to provide advice as to the suitability of investing in any product. Past performance is not a reliable indicator of future results. This financial promotion was approved on 16/01/2024.